[HTML][HTML] PD-L1 testing for lung cancer in 2019: perspective from the IASLC pathology committee
The recent development of immune checkpoint inhibitors (ICIs) has led to promising
advances in the treatment of patients with NSCLC and SCLC with advanced or metastatic …
advances in the treatment of patients with NSCLC and SCLC with advanced or metastatic …
Deep learning for lung cancer diagnosis, prognosis and prediction using histological and cytological images: a systematic review
Simple Summary Lung cancer is one of the most common and deadly malignancies
worldwide. Microscopic examination of histological and cytological lung specimens can be a …
worldwide. Microscopic examination of histological and cytological lung specimens can be a …
Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma
H Halse, AJ Colebatch, P Petrone, MA Henderson… - Scientific reports, 2018 - nature.com
A prospective study explored the heterogeneous nature of metastatic melanoma using
Multiplex immunohistochemistry (IHC) and flow cytometry (FACS). Multiplex IHC data …
Multiplex immunohistochemistry (IHC) and flow cytometry (FACS). Multiplex IHC data …
High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
S Ahn, J Lee, DW Shin, J Kim, JH Hwang - Scientific reports, 2020 - nature.com
Pembrolizumab appears promising for patients with programmed cell death ligand-1 (PD-
L1)-positive solid tumors. However, data on immunotherapy for biliary tract cancers (BTC) …
L1)-positive solid tumors. However, data on immunotherapy for biliary tract cancers (BTC) …
Analytical concordance of PD-L1 assays utilizing antibodies from FDA-approved diagnostics in advanced cancers: a systematic literature review
EA Prince, JK Sanzari, D Pandya, D Huron… - JCO Precision …, 2021 - ascopubs.org
PURPOSE Four programmed death ligand 1 (PD-L1) immunohistochemistry assays (28-8,
22C3, SP263, and SP142) have been approved for use by the US Food and Drug …
22C3, SP263, and SP142) have been approved for use by the US Food and Drug …
Deep semi supervised generative learning for automated tumor proportion scoring on NSCLC tissue needle biopsies
The level of PD-L1 expression in immunohistochemistry (IHC) assays is a key biomarker for
the identification of Non-Small-Cell-Lung-Cancer (NSCLC) patients that may respond to anti …
the identification of Non-Small-Cell-Lung-Cancer (NSCLC) patients that may respond to anti …
[HTML][HTML] PD-L1 testing in non-small cell lung cancer: past, present, and future
H Kim, JH Chung - Journal of pathology and translational medicine, 2019 - ncbi.nlm.nih.gov
Blockade of the programmed cell death-1 (PD-1) axis has already been established as an
effective treatment of non-small cell lung cancer. Immunohistochemistry (IHC) for …
effective treatment of non-small cell lung cancer. Immunohistochemistry (IHC) for …
[HTML][HTML] Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
R Govindan, C Aggarwal, SJ Antonia… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Immunotherapy has transformed lung cancer care in recent years. In addition to providing
durable responses and prolonged survival outcomes for a subset of patients with heavily …
durable responses and prolonged survival outcomes for a subset of patients with heavily …
Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional …
Background Programmed death-ligand 1 (PD-L1) monoclonal antibody therapy has recently
gained approval for treating metastatic triple-negative breast cancer (TNBC)-, in particular in …
gained approval for treating metastatic triple-negative breast cancer (TNBC)-, in particular in …
Domain adaptation-based deep learning for automated tumor cell (TC) scoring and survival analysis on PD-L1 stained tissue images
A Kapil, A Meier, K Steele, M Rebelatto… - … on Medical Imaging, 2021 - ieeexplore.ieee.org
We report the ability of two deep learning-based decision systems to stratify non-small cell
lung cancer (NSCLC) patients treated with checkpoint inhibitor therapy into two distinct …
lung cancer (NSCLC) patients treated with checkpoint inhibitor therapy into two distinct …